Inari Medical price target lowered to $65 from $84 at Wells Fargo

Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Inari Medical to $65 from $84 and keeps an Overweight rating on the shares. The firm notes Inari reported Q2 sales ahead of expectations and raised guidance by the Q2 beat. Management still sees 20% U.S. VTE market growth with Inari to remain the market leader. The company also announced the transition of CFO, Wells says.